SureTrader SureTrader
Home > Boards > US OTC > Biotechs >

Aeolus Pharmaceuticals (AOLS)

Add AOLS Price Alert      Hide Sticky   Hide Intro
Moderator: mick, Sheep
Search This Board:
Last Post: 10/13/2016 11:49:19 PM - Followers: 10 - Board type: Free - Posts Today: 0



Our strategy is to use non-dilutive capital wherever possible to develop our exciting platform of broad-spectrum catalytic antioxidant compounds in important unmet indications of national strategic importance.  We plan to continue to leverage that capital, like the investment made by U.S. government agencies, such as NIH-NIAID and NIH CounterACT, in AEOL 10150 as a medical countermeasure, to concurrently develop these promising compounds for use in significant unmet medical indications, like oncology. We are currently doing this with AEOL 10150, where we are leveraging the potential substantial government investment in research and development of AEOL 10150 as a medical countermeasure to develop the compound in oncology indications, where it would be used in combination with radiation therapy

Business Overview

 We are developing a platform of a new class of broad-spectrum catalytic antioxidant compounds based on technology discovered at Duke University and National Jewish Health. These compounds, known as metalloporphyrins, scavenge reactive oxygen species ("ROS") at the cellular level, mimicking the effect of the body's own natural antioxidant enzyme superoxide dismutase ("SOD").  While the benefits of antioxidants in reducing oxidative stress are well-known, research with our compounds indicates that metalloporphyrins can be used to affect signaling via ROS at the cellular level.  In addition, there is evidence that high-levels of ROS can affect gene expression and this may be modulated through the use of metalloporphyrins. We believe this could have a profound beneficial impact on people who have been exposed, or are about to be exposed, to high-doses of radiation.

Our lead compound, AEOL 10150, is a metalloporphyrin specifically designed to neutralize reactive oxygen and nitrogen species. The neutralization of these species reduces oxidative stress, inflammation, and subsequent tissue damage-signaling cascades resulting from radiation exposure.  We are leveraging the significant investment made by U.S. government agencies to develop this promising compound for use in oncology indications, where it would be used in combination with radiation therapy, and is currently in development for use as both a therapeutic and prophylactic drug. 

AEOL 10150 has previously been tested in two Phase I clinical trials with no serious adverse events reported.  Data have already been published showing that AEOL 10150 does not interfere with the therapeutic benefit of radiation therapy in prostate and lung cancer preclinical studies.  Early next year we expect to release data showing the drug's impact, if any, when used in combination with radiation and/or chemotherapy.  In mid-2011 we expect to begin Phase I/II studies in non-small cell lung cancer ("NSCLC").

AEOL 10150 is also being developed as a medical countermeasure against the pulmonary sub-syndrome of acute radiation syndrome ("Pulmonary Acute Radiation Syndrome" or "Lung-ARS") as well as the gastrointestinal sub-syndrome of acute radiation syndrome ("GI-ARS"), both caused by exposure to high levels of radiation due to a radiological or nuclear event.  It is also being developed for use as a countermeasure for exposure to chemical vesicants such as chlorine gas and sulfur mustard gas.  AEOL 10150 has already performed well in animal efficacy and safety studies in each of these potential indications.  A significant portion of the funding for the medical countermeasure development programs to date has come from various government entities.    Although our management expects this funding to continue, there is no guarantee that it will do so.  We have submitted proposals to the Biomedical Advanced Research and Development Authority ("BARDA") to develop AEOL 10150 as countermeasures for both Lung-ARS and cholorine gas exposure.  We are awaiting a final decision from BARDA on the contract.  If the contract from BARDA is awarded, it is expected that it will fund all of the costs to bring AEOL 10150 to FDA approval for that indication.

We have two programs underway for the development of our second drug candidate, AEOL 11207, for the treatment of epilepsy and Parkinson's disease.   These programs are being funded, in part, by private foundations and government grants.


 PDF Presentation Feb 2011:



Share Structure:

60,470,718 outstanding shares as of  MAY 10,2011
200,000,000 shares authorized

~ 6 - 9 Million shares in the Float
as of Jan 26, 2011



Point of Contact:

CFO: Russell Skibsted

Public Company, Headquarters Location
26361 Crown Valley Pkwy., Ste. 150, Mission Viejo, CA 92691-7324, United States
(949)481-9825, (949)481-9829 fax

AOLS (Daily)

AOLS (Weekly)


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
AOLS News: Current Report Filing (8-k) 09/13/2016 04:25:00 PM
AOLS News: Quarterly Report (10-q) 08/15/2016 04:15:53 PM
AOLS News: Current Report Filing (8-k) 05/26/2016 12:58:42 PM
AOLS News: Amended Quarterly Report (10-q/a) 05/16/2016 05:09:17 PM
AOLS News: Quarterly Report (10-q) 05/16/2016 06:04:29 AM
#235  Sticky Note 2015 Catalysts and Milestones Sheep 03/17/15 12:46:51 PM
#352   AOLS News: Current Report Filing (8-k) 09/13/2016 04:25:00 PM mick 10/13/16 11:49:19 PM
#351   Aeolus Pharmaceutica (AOLS) mick 10/13/16 11:49:14 PM
#350   If you have not looked at the latest Sheep 10/04/16 09:11:02 AM
#349   AOLS News: Current Report Filing (8-k) 09/13/2016 04:25:00 PM mick 10/01/16 09:23:14 AM
#348   Aeolus Pharmaceutica (AOLS) mick 10/01/16 09:23:08 AM
#347   I am still holding this. It is just Sheep 09/29/16 10:11:16 AM
#346   Noted. Huge buy 250K bid vs small avail ABNormal 09/27/16 07:04:08 PM
#345   AOLS News: Current Report Filing (8-k) 09/13/2016 04:25:00 PM mick 09/18/16 12:02:53 PM
#344   Aeolus Pharmaceutica (AOLS) mick 09/18/16 12:02:48 PM
#343   Great news: Sheep 09/06/16 01:14:34 PM
#342   AOLS News: Quarterly Report (10-q) 08/15/2016 04:15:53 PM mick 09/03/16 04:03:34 PM
#341   Aeolus Pharmaceutica (AOLS) mick 09/03/16 04:03:12 PM
#340   AOLS News: Current Report Filing (8-k) 05/26/2016 12:58:42 PM mick 08/13/16 05:23:44 PM
#339   Aeolus Pharmaceutica (AOLS) mick 08/13/16 05:23:30 PM
#338   AOLS News: Current Report Filing (8-k) 05/26/2016 12:58:42 PM mick 07/23/16 10:53:16 PM
#337   Aeolus Pharmaceutica (AOLS) mick 07/23/16 10:53:11 PM
#336   THANK YOU, mick 07/10/16 11:52:06 AM
#335   Listening to the CEO video conference sales can HokieHead 07/08/16 08:33:14 AM
#334   This thing is 5-10x undervalued here. Huge buying HokieHead 07/07/16 01:23:20 PM
#333   Oh they do, if you listen to their Sheep 07/06/16 03:03:44 PM
#332   Over $40,000 bought in an hour all the HokieHead 07/06/16 02:58:04 PM
#331   Nice run up today, someone was buying! Sheep 07/06/16 02:54:12 PM
#330   AOLS News: Current Report Filing (8-k) 05/26/2016 12:58:42 PM mick 06/21/16 04:53:43 PM
#329   Aeolus Pharmaceutica (AOLS) mick 06/21/16 04:53:35 PM
#328 mick 06/15/16 12:21:56 PM
#327   AOLS News: Current Report Filing (8-k) 05/26/2016 12:58:42 PM mick 05/30/16 01:22:02 PM
#326   Aeolus Pharmaceutica (AOLS) mick 05/30/16 01:21:47 PM
#325   AOLS News: Amended Quarterly Report (10-q/a) 05/16/2016 05:09:17 PM mick 05/20/16 02:32:06 PM
#324   Aeolus Pharmaceutica (AOLS) mick 05/20/16 02:31:51 PM
#323   Big volume after that call. Sheep 05/19/16 12:46:27 PM
#322   Very interesting conference call today! Sheep 05/19/16 11:44:18 AM
#321   AOLS News: Information Statement - All Other (definitive) mick 04/30/16 11:08:24 AM
#320   Aeolus Pharmaceutica (AOLS) mick 04/30/16 11:08:18 AM
#319   Nice Patent News! Sheep 04/19/16 10:20:25 AM
#318   AOLS News: Proxy Statement - Other Information (preliminary) mick 04/13/16 02:13:52 PM
#317   Aeolus Pharmaceutica (AOLS) mick 04/13/16 02:13:45 PM
#316 mick 03/26/16 03:43:26 PM
#315   While the RS news looks bad I don't Sheep 03/24/16 01:15:51 PM
#314   I think patience will eventually pay off here. devnull 03/03/16 11:25:15 AM
#313   I see we have someone building a large Sheep 03/03/16 11:06:14 AM
#312   AOLS News: Current Report Filing (8-k) 02/23/2016 12:39:43 PM mick 03/02/16 03:21:36 PM
#311   Aeolus Pharmaceutica (AOLS) mick 03/02/16 03:21:27 PM
#310   Yes, nice share structure: devnull 02/24/16 11:13:47 AM
#309   I love the fundamentals of this company. Sheep 02/24/16 09:37:47 AM
#308   AOLS AEOLUS PHARMACEUTICALS, INC. FILES (8-K) Disclosing Other HDOGTX 02/23/16 01:01:22 PM
#307   This is some major good news, wow. Sheep 02/22/16 08:46:27 AM
#306 davidsson10 02/22/16 08:12:34 AM
#305 mick 01/31/16 02:04:06 PM
#304 mick 01/26/16 11:20:14 PM
#303   McManus indicated a need for a sale to ABNormal 01/25/16 06:53:15 PM